Keyphrases
Route of Administration
100%
Immune Response
100%
Antigen Delivery System
100%
Particulate Antigen
100%
Cross-sectional Evaluation
100%
IgG2a
62%
Adjuvanted
50%
Delivery System
37%
Intralymphatic
37%
IgG1
25%
Particulate Delivery Systems
25%
Non-adjuvanted
25%
Liposomes
12%
Minor Differences
12%
Poly(lactide-co-glycolide)
12%
Vaccine Delivery System
12%
Antibody Response
12%
Subcutaneous Administration
12%
Next-generation Vaccines
12%
Material Properties
12%
Splenocytes
12%
Preclinical Research
12%
Ovalbumin
12%
Microparticles
12%
Nanoparticles
12%
Intramuscular Route
12%
Type 2 Immune Response
12%
Th1 Immune Response
12%
Th1 Response
12%
Preclinical Development
12%
IFN-γ Production
12%
Intradermal Route
12%
Polymeric Nanoparticles
12%
Titer
12%
Booster Immunization
12%
Polymeric Microparticles
12%
Liposome Nanoparticles
12%
Nanosized Particles
12%
Immune Response Modifier
12%
PLGA Microparticles
12%
Trimethyl chitosan Nanoparticles
12%
Loaded Liposomes
12%
Formulation Properties
12%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin G2a
100%
Route of Administration
100%
Liposome
60%
Microparticle
60%
Immunoglobulin G1
40%
Nanoparticle
40%
Clinical Research
20%
Polyglactin
20%
Subcutaneous Injection
20%
Intramuscular Route
20%
Ovalbumin
20%
Chitosan Nanoparticle
20%